Cue Other Assets from 2010 to 2024

CUE Stock  USD 1.62  0.01  0.61%   
Cue Biopharma's Other Assets are increasing over the years with slightly volatile fluctuation. Other Assets are expected to dwindle to about 2.1 M. During the period from 2010 to 2024 Cue Biopharma Other Assets annual values regression line had geometric mean of  506,517 and mean square error of 728.9 B. View All Fundamentals
 
Other Assets  
First Reported
2015-12-31
Previous Quarter
(1,000.00)
Current Value
(1,000.00)
Quarterly Volatility
2.3 M
 
Yuan Drop
 
Covid
Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 1.2 M or Selling General Administrative of 11.7 M, as well as many exotic indicators such as Price To Sales Ratio of 20.9, Dividend Yield of 0.0 or PTB Ratio of 3.09. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.
  
This module can also supplement Cue Biopharma's financial leverage analysis and stock options assessment as well as various Cue Biopharma Technical models . Check out the analysis of Cue Biopharma Correlation against competitors.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Latest Cue Biopharma's Other Assets Growth Pattern

Below is the plot of the Other Assets of Cue Biopharma over the last few years. It is Cue Biopharma's Other Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.
Other Assets10 Years Trend
Slightly volatile
   Other Assets   
       Timeline  

Cue Other Assets Regression Statistics

Arithmetic Mean1,453,210
Geometric Mean506,517
Coefficient Of Variation106.89
Mean Deviation1,429,253
Median198,282
Standard Deviation1,553,355
Sample Variance2.4T
Range3.8M
R-Value0.85
Mean Square Error728.9B
R-Squared0.72
Significance0.000064
Slope294,624
Total Sum of Squares33.8T

Cue Other Assets History

20242.1 M
20233.9 M
20223.4 M
2021M
20203.1 M
20193.4 M
2018M

About Cue Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cue Biopharma income statement, its balance sheet, and the statement of cash flows. Cue Biopharma investors use historical funamental indicators, such as Cue Biopharma's Other Assets, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may use each financial statement separately, they are all related. The changes in Cue Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cue Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cue Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Assets3.9 M2.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:
Check out the analysis of Cue Biopharma Correlation against competitors.
For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.
You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Cue Stock analysis

When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
CEOs Directory
Screen CEOs from public companies around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Cue Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.07)
Revenue Per Share
0.149
Quarterly Revenue Growth
8.182
Return On Assets
(0.47)
Return On Equity
(1.18)
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.